Aim Immunotech Inc (AIM) Stock Price, Quote & News

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 352 448 7797

Fax: 352 480 4620

Website: aimimmuno.com

Address:

2117 SW Highway 484, Ocala, United States

UncleAlbie Dec. 26 at 5:12 PM

$AIM Geez, what crap. Tom, you destroyed any potential opportunity for a profit. 99% down... I think it's time to give your Florida entrepreneur of the year award back.. You don't deserve anything..

1 · Reply

Leeman02 Dec. 26 at 2:48 PM

$AIM Nice chart.

1 · Reply

BillionerOfKing Dec. 25 at 7:38 PM

$AIM Current Stock Price: $1.28

0 · Reply

Teleboy Dec. 22 at 11:00 PM

$AIM Rintatolimod referenced in this article. The link refers to treating Pancreatic Cancer. https://link.springer.com/article/10.1186/s43556-025-00396-y

0 · Reply

TA_Kongen Dec. 22 at 6:52 PM

$AIM S-1 filed here. Might see the big ole' pump soon.

0 · Reply

WallStreetIsNotEasy Dec. 22 at 5:36 PM

$AIM is there really only 2.85 million shares?

1 · Reply

WallStreetIsNotEasy Dec. 20 at 3:30 PM

$AIM when’s the next data drop for pancreatic cancer with AstraZ

1 · Reply

resurrect_momo21 Dec. 19 at 1:27 PM

$AIM so pathetic he used to blame the naked shorts on this fake science pumping the stock meanwhile jai wei and his uncle tommy screwed everyone now he never posts 🤡

1 · Reply

ultimatebastos Dec. 19 at 12:33 PM

$AIM it’s clear who’s in charge now. And it ain’t retailors…

2 · Reply

uuddlrlr Dec. 18 at 8:40 PM

$AIM Results from annual shareholder meeting/vote had a few interesting items. Shareholders overall were disinterested in voting based on the numbers. Proposal 1 Kellner and Chemerow received the most votes of existing directors. Bryan and Equels received the fewest votes - Kellner (280,350), Chemerow (273,901), Mitchell (245,294), Equels (243,183), Bryan (240,688) Proposal 4 Strongest support of all proposals which was for an annual review of compensation.

0 · Reply

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Nov 18, 2025, 8:55 AM EST - 5 weeks ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Nov 12, 2025, 12:51 PM EST - 6 weeks ago

Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 8:55 AM EST - 6 weeks ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 4, 2025, 9:05 AM EST - 7 weeks ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Oct 20, 2025, 9:15 AM EDT - 2 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Sep 25, 2025, 8:45 AM EDT - 3 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 4, 2025, 11:00 AM EDT - 4 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Aug 21, 2025, 9:00 AM EDT - 4 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 15, 2025, 9:00 AM EDT - 4 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 8:55 AM EDT - 4 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 9:00 AM EDT - 5 months ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 4, 2025, 9:00 AM EDT - 5 months ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Jul 28, 2025, 11:12 AM EDT - 5 months ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 2, 2025, 8:55 AM EDT - 6 months ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jun 20, 2025, 4:15 PM EDT - 6 months ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 17, 2025, 8:55 AM EDT - 6 months ago

AIM ImmunoTech Resumes Trading on NYSE American

Jun 12, 2025, 8:30 AM EDT - 7 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:00 AM EDT - 7 months ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 11, 2025, 4:15 PM EDT - 7 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

May 13, 2025, 9:54 AM EDT - 8 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:45 AM EDT - 8 months ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

Apr 7, 2025, 1:26 PM EDT - 9 months ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 4, 2025, 4:45 PM EDT - 9 months ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:05 PM EDT - 9 months ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 1, 2025, 9:19 AM EDT - 9 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 9 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:45 AM EDT - 10 months ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 28, 2025, 8:45 AM EST - 10 months ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 26, 2025, 1:20 PM EST - 10 months ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 8:30 AM EST - 10 months ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 25, 2025, 8:30 AM EST - 10 months ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 11, 2025, 8:45 AM EST - 11 months ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:30 AM EST - 11 months ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 7, 2025, 8:50 AM EST - 11 months ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Jan 23, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 22, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 15, 2025, 9:05 AM EST - 1 year ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Dec 17, 2024, 4:45 PM EST - 1 year ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 3:10 PM EST - 1 year ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 16, 2024, 8:00 AM EST - 1 year ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Dec 14, 2024, 4:54 PM EST - 1 year ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Dec 12, 2024, 3:00 PM EST - 1 year ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Dec 12, 2024, 9:00 AM EST - 1 year ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Dec 12, 2024, 8:16 AM EST - 1 year ago

Kellner Group Announces Support from Another Former AIM Senior Executive

Dec 11, 2024, 7:30 AM EST - 1 year ago

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Dec 10, 2024, 10:20 AM EST - 1 year ago

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Dec 6, 2024, 9:15 AM EST - 1 year ago

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Dec 6, 2024, 8:34 AM EST - 1 year ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

UncleAlbie Dec. 26 at 5:12 PM

$AIM Geez, what crap. Tom, you destroyed any potential opportunity for a profit. 99% down... I think it's time to give your Florida entrepreneur of the year award back.. You don't deserve anything..

1 · Reply

Leeman02 Dec. 26 at 2:48 PM

$AIM Nice chart.

1 · Reply

BillionerOfKing Dec. 25 at 7:38 PM

$AIM Current Stock Price: $1.28

0 · Reply

Teleboy Dec. 22 at 11:00 PM

$AIM Rintatolimod referenced in this article. The link refers to treating Pancreatic Cancer. https://link.springer.com/article/10.1186/s43556-025-00396-y

0 · Reply

TA_Kongen Dec. 22 at 6:52 PM

$AIM S-1 filed here. Might see the big ole' pump soon.

0 · Reply

WallStreetIsNotEasy Dec. 22 at 5:36 PM

$AIM is there really only 2.85 million shares?

1 · Reply

WallStreetIsNotEasy Dec. 20 at 3:30 PM

$AIM when’s the next data drop for pancreatic cancer with AstraZ

1 · Reply

resurrect_momo21 Dec. 19 at 1:27 PM

$AIM so pathetic he used to blame the naked shorts on this fake science pumping the stock meanwhile jai wei and his uncle tommy screwed everyone now he never posts 🤡

1 · Reply

ultimatebastos Dec. 19 at 12:33 PM

$AIM it’s clear who’s in charge now. And it ain’t retailors…

2 · Reply

uuddlrlr Dec. 18 at 8:40 PM

0 · Reply

theflynews Dec. 18 at 5:06 PM

Biotech Alert: Searches spiking for these stocks today - $AIM - https://thefly.com/permalinks/entry.php/AIMid4259691?1766077054C38

0 · Reply

Teleboy Dec. 18 at 3:04 PM

$AIM Rintatolimod referenced heavily in this: "The striking overlap in genes and mechanisms between long COVID and ME (76 / 180 long COVID genes tested) suggests the potential for development of novel or repurposed drug therapies that could be used to successfully treat either condition. However, although they share significant genetic commonalities, long COVID and ME appear to be best considered as partially overlapping but different diseases." https://www.researchgate.net/publication/398489836_Identification_of_Novel_Reproducible_Combinatorial_Genetic_Risk_Factors_for_Myalgic_Encephalomyelitis_in_the_DecodeME_Patient_Cohort_and_Commonalities_with_Long_COVID

0 · Reply

Teleboy Dec. 17 at 9:46 PM

$AIM Vote is in: 8-K Board reelected! https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-25-028156.htm

1 · Reply

Teleboy Dec. 17 at 3:16 PM

$AIM PWC looking ahead to next year in BioPharma: https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html

0 · Reply

Teleboy Dec. 17 at 3:09 PM

$AIM Last year AIM put out a press release with the preliminary results of the board vote on the same day as the meeting. They provided the full results in an 8-K three days later.

2 · Reply

sschmid1 Dec. 17 at 7:39 AM

$AIM AIM mentioned as a potential leader in the battle against stolid tumors https://www.newswire.ca/news-releases/immunotherapy-breakthroughs-turn-cold-gi-tumors-hot-as-market-tops-443b-821609911.html

0 · Reply

Teleboy Dec. 16 at 5:59 PM

$AIM Did anyone listen to or attend the meeting? I couldn't this year.

0 · Reply

rayk1 Dec. 15 at 3:49 PM

$AIM MC now 3,7 Million USD??? Great job Equels,you deserve to be the forever CEO of this Scam!!! And keep laughing with your yearly more then a million Dollar paycheck🤮🤮🤮

0 · Reply

Leeman02 Dec. 15 at 1:36 PM

$AIM Hey everyone get in line to buy your preferred shares at only 1000$ each.

2 · Reply

rayk1 Dec. 14 at 10:41 PM

$AIM this guy still around???🤮

0 · Reply

ultimatebastos Dec. 13 at 7:56 PM

$AIM the vote is a joke retailors have nothing to say anymore thanks to the criminal naked shorts. But 3% stays 3%

0 · Reply

uuddlrlr Dec. 12 at 10:39 PM

$AIM What happened to all the posters who were cheerleaders for CEO Equels and the legacy board in the 2024 vote? The vote was roughly 1 year ago. Since then the incompetent CEO Equels and his leadership team have achieved the following: - Stock is down 93% in a year - 1:100 reverse split - Dilution and more dilution on the horizon A random person off stocktwits could have delivered the same results and saved the company money with lower compensation. Please give shareholders some hope by relieving the CEO and COO of all responsibilities

2 · Reply

Market Cap	3.65M
Revenue (ttm)	170,000.00
Net Income (ttm)	-17.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,188.24%
Debt to Equity Ratio	0.00

Volume	51,610
Avg Vol	72,978
Day's Range	N/A - N/A
Shares Out	2.85M
Stochastic %K	6%
Beta	1.19
Analysts	Sell
Price Target	$14.00